Oncotarget Early prediction of resistance to tyrosine kinase inhibitors
Oncotarget Volume 11, Issue 11 reported that at clinical progression, 64 EGFR T790M plasma positive patients were subjected to second line-treatment with osimertinib and strictly...
















